Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SOLESENCE, INC.NANX · Entity 7041 | Director · President, CEO | December 31, 2024 | January 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SOLESENCE, INC.
Report date December 31, 2024 · Filed January 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2031-12-31 | Direct | 22,500 |
Reported balance
After 2024-12-31 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-12-31 · Grant · Acquired 22,500 · Balance 22,500 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2026-02-23 | Direct | 69,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 69,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2027-02-21 | Direct | 81,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 81,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-05-23 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 90,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2029-05-22 | Direct | 16,500 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 16,500 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2027-06-18 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 90,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.17 · Expires 2028-12-28 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 90,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2029-12-20 | Direct | 72,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 72,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2030-12-27 | Direct | 12,600 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 12,600 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common StockSEC Table I · non-derivative | IndirectSpouse's IRA | 1,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,000 |
| Common StockSEC Table I · non-derivative | Direct | 207,450 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 207,450 |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2024 Filed Jan 13, 2025 22:29 UTC | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to purchase) · Derivative | 22,500 | $2.44 Strike: $2.44 | $54,900.00 |
DisclosureSEC source: 0000950170-25-004913 · ownership.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-12-31 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 20:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Disposition to issuerCommon Stock (right to purchase) · Derivative | 81,000 | $0.44 Strike: $0.44 | $35,640.00 |
DisclosureSEC source: 0000950170-24-109325 · ownership.xml · derivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,000 shares Expires 2025-02-18 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 20:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 81,000 | $0.44 | $35,964.00 |
DisclosureSEC source: 0000950170-24-109325 · ownership.xml · nonDerivative · entry 2 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 21:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | PurchaseCommon Stock | 7,008 | $0.40 | $2,803.20 |
DisclosureSEC source: 0001209191-24-003167 · doc4.xml · nonDerivative · entry 2 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,458 F1 · price: These shares were purchased as part of the Company's recent shareholder rights offering. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 11:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Disposition to issuerCommon Stock (right to purchase) · Derivative | 67,450 | $0.52 Strike: $0.52 | $35,074.00 |
DisclosureSEC source: 0001209191-24-002024 · doc4.xml · derivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,450 shares Expires 2024-02-13 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 11:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 67,450 | $0.52 | $35,074.00 |
DisclosureSEC source: 0001209191-24-002024 · doc4.xml · nonDerivative · entry 2 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to purchase) · Derivative | 12,600 | $0.61 Strike: $0.61 | $7,686.00 |
DisclosureSEC source: 0001209191-23-059982 · doc4.xml · derivative · entry 12 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,600 Underlying: Common Stock · 12,600 shares Expires 2030-12-27 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments. Read SEC document |
| September 08, 2023 Filed Sep 9, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,500 | $0.52 Strike: $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048852 · doc4.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,450 Underlying: Common Stock · 69,950 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F5 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments. Read SEC document |
| September 08, 2023 Filed Sep 9, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,500 | $1.00 | $2,500.00 |
DisclosureSEC source: 0001209191-23-048852 · doc4.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| September 08, 2023 Filed Sep 9, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,500 | $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048852 · doc4.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| September 07, 2023 Filed Sep 9, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,500 | $0.52 Strike: $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048852 · doc4.xml · derivative · entry 10 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,950 Underlying: Common Stock · 72,450 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F4 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
| September 07, 2023 Filed Sep 9, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,500 | $1.00 | $2,500.00 |
DisclosureSEC source: 0001209191-23-048852 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| September 07, 2023 Filed Sep 9, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,500 | $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048852 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| September 06, 2023 Filed Sep 9, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 1,000 | $0.52 Strike: $0.52 | $520.00 |
DisclosureSEC source: 0001209191-23-048852 · doc4.xml · derivative · entry 9 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,450 Underlying: Common Stock · 73,450 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F4 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
| September 06, 2023 Filed Sep 9, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,000 | $1.00 | $1,000.00 |
DisclosureSEC source: 0001209191-23-048852 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| September 06, 2023 Filed Sep 9, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,000 | $0.52 | $520.00 |
DisclosureSEC source: 0001209191-23-048852 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,500 | $0.52 Strike: $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048252 · doc4.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,450 Underlying: Common Stock · 75,950 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F5 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,500 | $1.01 | $2,535.00 |
DisclosureSEC source: 0001209191-23-048252 · doc4.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,500 | $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048252 · doc4.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,500 | $0.52 Strike: $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048252 · doc4.xml · derivative · entry 10 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,950 Underlying: Common Stock · 78,450 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F4 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,500 | $1.00 | $2,500.00 |
DisclosureSEC source: 0001209191-23-048252 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,500 | $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048252 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| August 31, 2023 Filed Sep 6, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,500 | $0.52 Strike: $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048252 · doc4.xml · derivative · entry 9 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,450 Underlying: Common Stock · 80,950 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F4 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
| August 31, 2023 Filed Sep 6, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,500 | $1.00 | $2,500.00 |
DisclosureSEC source: 0001209191-23-048252 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| August 31, 2023 Filed Sep 6, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,500 | $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-048252 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 22:40 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,500 | $0.52 Strike: $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-047878 · doc4.xml · derivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,950 Underlying: Common Stock · 83,450 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F4 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 22:40 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,500 | $1.00 | $2,500.00 |
DisclosureSEC source: 0001209191-23-047878 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 22:40 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,500 | $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-047878 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 22:40 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,500 | $0.52 Strike: $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-047878 · doc4.xml · derivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,450 Underlying: Common Stock · 85,950 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F4 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 22:40 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,500 | $1.00 | $2,500.00 |
DisclosureSEC source: 0001209191-23-047878 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 22:40 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,500 | $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-047878 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 500 | $0.52 Strike: $0.52 | $260.00 |
DisclosureSEC source: 0001209191-23-047549 · doc4.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,950 Underlying: Common Stock · 86,450 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F4 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 500 | $1.00 | $500.00 |
DisclosureSEC source: 0001209191-23-047549 · doc4.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 500 | $1.00 | $500.00 |
DisclosureSEC source: 0001209191-23-047549 · doc4.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 1,050 | $0.52 Strike: $0.52 | $546.00 |
DisclosureSEC source: 0001209191-23-047549 · doc4.xml · derivative · entry 10 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,450 Underlying: Common Stock · 87,500 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F4 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,050 | $1.02 | $1,065.75 |
DisclosureSEC source: 0001209191-23-047549 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,050 | $0.52 | $546.00 |
DisclosureSEC source: 0001209191-23-047549 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| August 24, 2023 Filed Aug 29, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,500 | $0.52 Strike: $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-047549 · doc4.xml · derivative · entry 9 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 90,000 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F4 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
| August 24, 2023 Filed Aug 29, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,500 | $1.01 | $2,512.50 |
DisclosureSEC source: 0001209191-23-047549 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 F2 · shares: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders. Read SEC document |
| August 24, 2023 Filed Aug 29, 2023 00:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,500 | $0.52 | $1,300.00 |
DisclosureSEC source: 0001209191-23-047549 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:27 UTC | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to purchase) · Derivative | 72,000 | $1.17 Strike: $1.17 | $83,880.00 |
DisclosureSEC source: 0001209191-22-062393 · doc4.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2029-12-20 F2 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 1,514 | $0.42 Strike: $0.42 | $628.31 |
DisclosureSEC source: 0001209191-22-061552 · doc4.xml · derivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,296 Underlying: Common Stock · 5,810 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,514 | $1.24 | $1,877.36 |
DisclosureSEC source: 0001209191-22-061552 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F2 · date: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. F4 · price: These shares were sold in eleven separate transactions, ranging from $1.20 and $1.30 per share. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,514 | $0.42 | $628.31 |
DisclosureSEC source: 0001209191-22-061552 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| December 13, 2022 Filed Dec 16, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 400 | $0.42 Strike: $0.42 | $166.00 |
DisclosureSEC source: 0001209191-22-061552 · doc4.xml · derivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,810 Underlying: Common Stock · 6,210 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| December 13, 2022 Filed Dec 16, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 400 | $1.35 | $540.00 |
DisclosureSEC source: 0001209191-22-061552 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F2 · date: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. F3 · price: These shares were sold in three separate transactions, ranging from $1.34 and $1.37 per share. Read SEC document |
| December 13, 2022 Filed Dec 16, 2022 02:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 400 | $0.42 | $166.00 |
DisclosureSEC source: 0001209191-22-061552 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 01:10 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 15,100 | $0.42 Strike: $0.42 | $6,266.50 |
DisclosureSEC source: 0001209191-22-060425 · doc4.xml · derivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,210 Underlying: Common Stock · 21,310 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 01:10 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 15,100 | $1.18 | $17,818.00 |
DisclosureSEC source: 0001209191-22-060425 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 F2 · date: If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. F4 · price: These shares were sold in six separate transactions, all at $1.18 per share. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 01:10 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 15,100 | $0.42 | $6,266.50 |
DisclosureSEC source: 0001209191-22-060425 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.